Form 4: Director Gerald McLaughlin Acquires Allarity Shares

Director Gerald W. McLaughlin acquired 45,000 shares of Allarity Therapeutics, Inc. common stock via a restricted stock unit grant.

Summary

• Director Gerald W. McLaughlin received a grant of 45,000 restricted stock units (RSUs) on January 28, 2026.
• The RSUs vested in full immediately upon the grant date.
• Following this transaction, the director's total beneficial ownership of common stock increased to 70,000 shares.
• The shares were acquired at a price of $0 per share under the company's Amended and Restated 2021 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Increased equity alignment between the director and shareholders.
• Full vesting of equity grants indicates immediate commitment to the company's long-term success.

Negatives

• None identified in this filing.

Risks

• Equity-based compensation may dilute existing shareholders if not managed within authorized share pools.

Future Outlook

No specific forward-looking guidance provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that director equity grants are standard practice in the biotechnology sector to align leadership interests with shareholder value, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The use of equity incentive plans for director compensation is consistent with standard corporate governance practices for small-cap biotech firms.
• Immediate vesting of director RSUs is a common mechanism to provide compensation for board service.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new equity.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Allarity Therapeutics, ALLR, Insider Trading, Form 4, Equity Incentive Plan, Director Ownership